HOME >> MEDICINE >> NEWS
Structure of key cancer drug target identified

Researchers from Monash's Department of Biochemistry and Molecular Biology have determined the structure of the protein JAK2 kinase, a discovery with huge implications for the design and development of new cancer drugs.

NHMRC Industry Research Fellow Dr Isabelle Lucet, from Monash's Protein Crystallography Unit headed by Dr Jamie Rossjohn, was part of the team that determined the structure. JAK2 kinase was the driving force for many cancers and cardiovascular disorders, she said.

The research, partly funded by a $1.2 million Australian Research Council Linkage Grant, was a joint project between drug development company Cytopia Limited and the Protein Crystallography Unit.

The JAK kinases, which were first discovered by Cytopia's chief scientific officer Dr Andrew Wilks, are a well-validated drug target.

Dr Lucet said the discovery of JAK2 kinase's structure had allowed an internationally competitive structure-based drug design on JAK kinase inhibitors to begin.

"This will help the development of drugs for cancer and other disorders by assisting with the design of specific molecules."

She said the high expertise of the Monash research team, combined with the drug discovery capability of Cytopia, would undoubtedly enable more selective drug targets to be developed against diseases where the JAK kinases play a pivotal role.

Dr Lucet said the new discovery would allow the rapid growth of a portfolio of phase I therapeutics.


'"/>

Contact: Penny Fannin
61-3-9905-5828
Research Australia
25-Oct-2005


Page: 1

Related medicine news :

1. Structure essential for brain remodeling identified
2. Structure of viral harpoon protein reveals how viruses enter cells
3. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
4. Survival differences by race most apparent in advanced stages of breast cancer
5. Stomach cancer rate set to fall further 25 percent over next decade
6. MRI finds breast cancer before it becomes dangerous
7. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
8. New cause of tamoxifen resistance in breast cancer cells discovered at Lombardi
9. Pathway links inflammation, angiogenesis and breast cancer
10. Using MRI for diagnosis could help prevent breast cancer progression
11. Electric fields have potential as a cancer treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/19/2017)... ... September 19, 2017 , ... Leonard I. Linkow, DDS, DMSC, ... ” (published by Xlibris on July of 2014). This book details the recent advances ... methodological approaches that benefit people who have lost all of their natural teeth ...
(Date:9/19/2017)... PA (PRWEB) , ... September 19, 2017 , ... ... orthopedic dog beds, has been officially recognized for its September 2016 donation of ... , The company recently received three awards and honors for its contribution from ...
(Date:9/19/2017)... Montclair, NJ (PRWEB) , ... September 19, 2017 ... ... fall following the success of the annual PAINWeek National Conference. On October 7, ... will be an educational and exciting program providing busy clinicians and allied healthcare ...
(Date:9/19/2017)... ... 19, 2017 , ... Bone Solutions Inc. (BSI), an orthobiologics ... medical device, OsteoCrete®. OsteoCrete® bone void filler is designed to assist with bone ... a critical property for bone health and development. , “We’re excited to bring ...
(Date:9/19/2017)... ... September 19, 2017 , ... Premiere Long Island dental office Gold ... named one of the best dentists in America under age 40 by Incisal Edge ... Every fall, the magazine features the best 40 dentists under the age of 40 ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
(Date:9/1/2017)... N.J. , Sept. 1, 2017  Bayer will present ... the European Society for Medical Oncology (ESMO) 2017 Congress, September ... presented will include new preclinical and clinical data on Bayer,s ... two earlier pipeline projects. ... the best minds in cancer research at ESMO," said ...
(Date:8/29/2017)... Aug. 29, 2017 In a move that ... regulatory compliance for veterinary practices of all sizes, Cubex ... partnership that makes TITAN,s expertise in physical security, drug ... Cubex,s clients nationally. ... handling controlled substances is at risk today," said TITAN ...
Breaking Medicine Technology:
Cached News: